M&A moves are down, venture rounds few and IPOs nonexistent.
The long-awaited US approval of its newest artificial pancreas comes through, but Medtronic remains behind.
The group is fast developing its new atrial fibrillation devices. But will it be fast enough?
The promise of fast timelines and early revenues lure a new investor into digital medicine.